{
  "ticker": "RCE",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02976949",
  "id": "02976949",
  "pages": 3,
  "price_sensitive": false,
  "date": "20250805",
  "time": "0944",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250805/pdf/06mjxt7wjf1vqp.pdf",
  "summary": "- **Event Announcement**: Recce Pharmaceuticals presenting Abstract & Poster at 2025 Military Health System Research Symposium (MHSRS), showcasing RECCE\u00ae 327's lab-tested efficacy against bioterrorism pathogens (Anthrax, Tularemia, Glanders, Melioidosis, Plague).  \n- **USAMRIID Collaboration**: Ongoing testing under a CRADA with USAMRIID against biodefense pathogens.  \n- **Funding**: US$2M grant from U.S. DoD\u2019s CDMRP for burn wound treatment development (R327G).  \n\n*No material trading or capital markets impact identified.*",
  "usage": {
    "prompt_tokens": 1905,
    "completion_tokens": 132,
    "total_tokens": 2037,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-08-05T00:06:08.149768"
}